Enavate Sciences Gp, LLC reported 7 holdings worth US$345M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Enavate Sciences Gp, LLC reported 7 holdings worth US$345M as of Jun 30, 2026. Largest: Sionna Therapeutics, Inc., Zenas Biopharma, Inc. and Immunome, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 7
- Value as reported
- US$345M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Sionna Therapeutics, Inc. | 2.48M | US$109M | 31.6% |
| Zenas Biopharma, Inc. | 3.92M | US$99.5M | 28.8% |
| Immunome, Inc. | 3.61M | US$76.6M | 22.2% |
| Bridgebio Oncology Therapeutics, Inc. | 2.63M | US$20M | 5.8% |
| Compass Therapeutics, Inc. | 7.79M | US$17.1M | 4.9% |
| Upstream Bio, Inc. | 2.46M | US$17M | 4.9% |
| Camp4 Therapeutics Corporation | 1.43M | US$6.23M | 1.8% |